(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 February 2006 (16.02.2006)

PCT

(10) International Publication Number
WO 2006/016178 A1

(51) International Patent Classification:
C07D 405/06 (2006.01)   *A61K 31/4025* (2006.01)
C07D 309/04 (2006.01)

(21) International Application Number:
PCT/GB2005/003175

(22) International Filing Date: 12 August 2005 (12.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0418046.9   12 August 2004 (12.08.2004)   GB

(71) Applicant *(for all designated States except US)*: **PROSID-ION LIMITED** [GB/GB]; Watlington Road, Oxford, Oxfordshire OX4 6LT (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BRINER, Paul, Howard** [GB/GB]; Prosidion Limited, Watlington Road, Oxford, Oxfordshire OX4 6LT (GB). **FYFE, Matthew, Colin, Thor** [GB/GB]; Prosidion Limited, Watlington Road, Oxford, Oxfordshire OX4 6LT (GB). **MADELEY, John, Paul** [GB/GB]; Prosidion Limited, Watlington Road, Oxford, Oxfordshire OX4 6LT (GB). **MURRAY, Peter, John** [GB/GB]; Prosidion Limited, Watlington Road, Oxford, Oxfordshire OX4 6LT (GB). **PROCTER, Martin, James** [GB/GB]; Prosidion Limited, Watlington Road, Oxford, Oxfordshire OX4 6LT (GB). **SPINDLER, Felix** [CH/CH]; Solvias AG, WRO-1055.6.30, Mattenstrasse 22, 4002 Basel (CH).

(74) Agent: BLAKEY, Alison; Prosidion Limited, Watlington Road, Oxford, Oxfordshire OX4 6LT (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ENANTIOSELECTIVE PROCESS

(57) Abstract: A process for the production of compounds comprising the enantioselective hydrogenation of 2-substituted acrylic acid derivatives.

ENANTIOSELECTIVE PROCESS

BACKGROUND OF THE INVENTION

The present invention is directed to a process for the enantioselective production of

5   compounds. In particular, the invention is directed to a method for the enantioselective

hydrogenation of compounds of use in the production of pharmaceutically active compounds,

especially compounds which are useful as activators of glucokinase for the treatment of type

II diabetes.

Methods for the enantioselective hydrogenation of functionalized olefins, ketones and

10   imines are known in the art. However, the enantioselective hydrogenation of 2-substituted

acrylic acids has proved less successful than the enantioselective hydrogenation of other

starting materials, such as α-enamides, as the substituent in the 2-position has a considerable

impact on the degree of enantioselectivity that can be achieved.

The purity of pharmaceutical compounds to be used for methods of treatment is of

15   paramount importance, thus for example, the synthesis of pharmaceutically active compounds

of high enantiomeric purity on a commercial scale is a challenge for the pharmaceutical

industry.

International Patent Application PCT/US04/03968 (published after the priority date of

the present application) discloses various tri(cyclo) substituted amide compounds which are

20   modulators of glucokinase and are useful in the prophylactic or therapeutic treatment of

hyperglycemia and diabetes, in particular type II diabetes. Certain of these compounds, for

example (2R)-2-(4-cyclobutanesulfonyl phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-

yl)propionamide, (2R)-2-(4-cyclobutanesulfonylphenyl)-N-(1-methyl-1H-pyrazol-3-yl)-3-

(tetrahydropyran-4-yl)propionamide, (2R)-2-(4-cyclobutanesulfonylphenyl)-N-(5-

25   fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide, (2R)-2-(4-

cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide

and (2R)-2-(4-cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-

yl)propionamide, have a chiral center thus there is a need for efficient processes for the

production of such compounds of high enantiomeric purity.

30   PCT/US04/03968 describes the synthesis of such compounds by condensation of the

corresponding chiral acid:

for example where R is cyclobutyl or cyclopropyl, and the corresponding heteroaromatic amine.

The (2R)-propionic acid compound is produced from the corresponding racemic acid i.e. 2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid or 2-(4-
5   cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid by condensing with a chiral oxazolidinone derivative to generate a mixture of diastereoisomeric imides that are separable by any conventional method, e.g. column chromatography. Hydrolysis of the pure imides affords the stereopure (2R)-propionic acids that can then be condensed with heterocyclic amines employing a reagent that minimises racemisation of the chiral centre, e.g.
10   benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate.

However, this process is not particularly efficient for the synthesis of such compounds on a commercial scale. Therefore there is a need for further efficient processes for the production of such compounds of high enantiomeric purity and yield.

15   SUMMARY OF THE INVENTION
A process for the production of compounds comprising the enantioselective hydrogenation of 2-substituted acrylic acid derivatives.

DETAILED DESCRIPTION OF THE INVENTION
20   The present invention provides a process for the production of a compound of formula (I):

(I)

wherein R is cyclopropyl or cyclobutyl, comprising the enantioselective hydrogenation of a
25   compound of formula (II):

(II)

wherein the double bond is in the (E)-configuration and R is cyclopropyl or cyclobutyl.

The hydrogenation of the compounds of formula (II) is preferably conducted in the presence of a rhodium or ruthenium catalyst. The catalyst is preferably an anionic, neutral or cationic rhodium catalyst, more preferably a cationic rhodium catalyst. The catalyst is preferably generated *in situ*, for example from [Rh(nbd)$_2$]BF$_4$, [Rh(nbd)Cl]$_2$, or [RuI$_2$(p-cymeme)]$_2$ and a suitable ligand (nbd = norbornadiene). Alternatively the catalyst may be isolated before use.

Suitable ligands include diphosphine and phosphine ligands, preferably atropisomeric diphosphines, which may have additionally a chiral carbon atom (see M. Scalone Tetrahedron Asymmetry, 1997, 8, 3617; T. Uemura, J. Org. Chem., 1996, 61, 5510; and X. Zhang Synlett, 1994, 501), chiral diphosphine ligands such as for example Josiphos (EP-A-0612758), Walphos (F. Spindler, Adv. Synth. Catal., 2003, 345,1; EP-A-1 1236994; and US-6777567), Phospholane (CH0813/03), Mandyphos (EP-A-0965574; DE-A-1 19921924; and DE-A-1 19956374), Taniaphos (DE-A-1 19952348) and other ferrocene ligands such as for example Jafaphos (EP-A1-803510).

Particularly preferred are ferrocene ligands, for example Mandyphos ligands as described in EP-A-965574. Preferred Mandyphos ligands have the structure:


wherein G and G' which may be the same or different are selected from phenyl optionally substituted with one or more substituents selected from C$_{1-4}$alkyl and methoxy, e.g. 2-MePh, 3,5-diMePh or 3,5-diMe-4-MeOPh;

R is phenyl or methyl, e.g. phenyl; and

R' are independently selected from C$_{1-4}$alkyl, e.g. methyl.

Particular Mandyphos ligands which may be mentioned include (R)-(S)-MOD-Mandyphos and xyl-Mandyphos, especially (R)-(S)-MOD-Mandyphos (structure shown below):

(R)-(S)-MOD-Mandyphos

A particularly preferred catalyst/ligand combination is [Rh(nbd)$_2$]BF$_4$ / (R)-(S)-MOD-
Mandyphos.

The hydrogenation pressure used in the process of the invention is preferably up to
about 100 bar, such as in the range of 5-100 bar, such as 5-50 bar, for example 15-50 bar.

The temperature used in the process of the invention is preferably up to about 100°C,
such as in the range of room temperature to 80°C, e.g. 30-80°C, preferably about 30°C.

The process of the invention is preferably conducted in solution. Suitable solvents
include alcoholic solvents, for example methanol, ethanol and iso-propanol. It is particularly
preferred that a mixed solvent is used, for example, a mixture of an alcoholic solvent and an
arene solvent, e.g. benzene or toluene, preferably toluene, or a mixture of an alcoholic solvent
and dimethoxyether, trifluoroethanol or dichloromethane. Suitable mixed solvents include
mixtures of alcoholic solvents and toluene, e.g. methanol and toluene. A preferred solvent
mixture is 1:1 to 10:1v/v methanol:toluene, especially about 5:1v/v methanol:toluene. A
further preferred solvent mixture is 1:1 to 10:1v/v ethanol:toluene, especially about 5:1v/v
ethanol:toluene.

The process of the invention may also be conducted in the presence of base additives
e.g. KOH or amines such as NEt$_3$. A preferred base additive is NEt$_3$ which may be added to
the hydrogenation mixture in an amount of about 10eq/Rh or Ru.

The (R)-acid of formula (I) may also be further enantiomerically enriched, e.g. by
recrystallisation. Suitable solvents for recrystalisation include isopropylacetate,
isobutylacetate and ethylacetate, preferably isobutylacetate and mixed solvents such as
isobutylacetate or ethylacetate and heptane. A preferred solvent mixture is isobutyl acetate
and heptane at a ratio of 20:1 to 1:1v/v e.g. 9:1v/v. Other solvents include water:acetic acid
e.g. 1:1v/v, and 1-butanol.

The (R)-acid of formula (I) produced according to the process of the invention
preferably has ≥85% ee, more preferably ≥90% ee, even more preferably ≥95% ee, and
especially ≥98% ee.

The (E)-acids of formula (II) may be prepared as described in the Examples, or by processes analogous thereto. The (E)-acid of formula (II) used in the method of the invention should be as pure as possible. The (E)-acid of formula (II) is preferably washed with water prior to its use as a substrate in the hydrogenation reaction e.g. to remove any chloride ions

5 which may be present.

The invention also provides the use of the compounds of formula (I) prepared as described above as an intermediate for the manufacture of a compound of formula (III), or a pharmaceutically acceptable salt thereof:

10

(III)

wherein R is cyclopropyl or cyclobutyl;

T together with the $-N=C-$ to which it is attached forms a heteroaryl ring, or a heterocyclic ring where the $N=C$ bond is the only site of unsaturation;

15 R^3 and R^4 each independently are hydrogen, halogen, OCF_nH_{3-n}, methoxy, CO_2R^5, cyano, nitro, CHO, $CONR^6R^7$, $CON(OCH_3)CH_3$, or C_{1-2}alkyl, heteroaryl, or C_{3-7}cycloalkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, $-NHCO_2CH_3$, or $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$ substituents; or R^3 and R^4 together form a 5–8-membered aromatic, heteroaromatic, carbocyclic, or heterocyclic ring;

20 R^5 is hydrogen, or a C_{1-4}alkyl group, C_{2-4}alkenyl group, C_{2-4}alkynyl group, C_{3-7}cycloalkyl group, aryl group, heteroaryl group, or 4–7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C_{1-2}alkoxy, $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$, C_{1-2}alkyl, C_{3-7}cycloalkyl, 4–7-membered heterocyclic ring, CF_nH_{3-n}, aryl, heteroaryl, CO_2H, $-COC_{1-2}alkyl$, $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, $SOCH_3$, SO_2CH_3, or $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$ substituents;

25

R^6 and R^7 each independently are hydrogen, or C_{1-4}alkyl group, C_{3-7}cycloalkyl group, aryl group, heteroaryl group, or 4–7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C_{1-2}alkoxy, $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$, C_{1-2}alkyl, C_{3-7}cycloalkyl, 4–7-membered heterocyclic ring, CF_nH_{3-n},

30 aryl, heteroaryl, $COC_{1-2}alkyl$, $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, $SOCH_3$, SO_2CH_3, or $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$ substituents; or R^6 and R^7 together form a 6–8-membered heterobicyclic

ring system or a 4–8-membered heterocyclic ring which optionally is substituted with 1–2 independent C_{1-2}alkyl, CH_2OCH_3, COC_{0-2}alkyl, hydroxy, or SO_2CH_3 substituents; and

n is 1, 2 or 3.

The compounds of formula (III) may be prepared by the condensation of the carboxylic acid of formula (I) with an amine of formula (IV), or a salt thereof:

$$H_2N \underset{N}{\overset{R^3}{\diagup}} R^4$$

(IV)

wherein R^3 and R^4 are as defined above, using a variety of coupling conditions, e.g. polymer supported carbodiimide-1-hydroxybenzotriazole in N,N-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdf and available from Argonaut Technologies, Inc., Foster City, California). Alternatively, a compound of formula (III) may be prepared by condensing amine (IV), or a salt thereof, with an activated acid derivative, such as the corresponding acid chloride. Preferably the condensation is performed employing a reagent that minimises racemisation of the chiral centre, e.g. benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (J. Coste et al. *Tetrahedron Lett.* **1990**, *31*, 205–208), to furnish enantiopure (*R*)-amides of formula (III).

Alternatively the coupling reaction may employ an activated derivative of the carboxylic acid of formula (IV), for example a protected ester or acid chloride thereof which may be prepared by methods known to those skilled in the art, in which case the coupling may be conducted in the presence of collidine or another suitable pyridine derivative.

The acid chloride derivatives of the compounds of formula (I) are novel. Thus according to a further aspect of the invention there is provided a compound of formula (V):

(V)

wherein R is cyclopropyl or cyclobutyl.

The acid chlorides of formula (V) may be prepared from the corresponding acids of formula (I) by methods known in the art. The acid chloride may be prepared for example by reaction of the compounds of formula (I) with oxalyl chloride or thionyl chloride in a suitable

solvent, such as dichloromethane. The acid chloride may be isolated but is preferably generated *in situ* prior to coupling with an amine of formula (IV).

Preferred compounds of formula (III) prepared according to this aspect of the invention include those compounds wherein T together with the –N=C– to which it is attached

5   forms a 2-pyrazinyl or 2-thiazolyl ring, and R^3 and R^4 each independently are hydrogen, methyl or fluoro. In particular compounds wherein T together with the –N=C– to which it is attached forms a 5-fluorothiazol-2-yl group. In another embodiment of the invention, compounds of formula (III) include those compounds wherein T together with the –N=C– to which it is attached forms form a 3-pyrazolyl ring, wherein R^3 and R^4 are independently

10   hydrogen or C_{1-2}alkyl, for example a 1-methylpyrazol-3-yl group.

The invention also provides a pharmaceutical composition comprising a compound of formula (III), or a pharmaceutically acceptable salt thereof, produced according to the method described above, in combination with a pharmaceutically acceptable diluent or carrier.

The invention also provides a method of prophylactic or therapeutic treatment of a

15   condition where activation of glucokinase is desirable comprising a step of administering an effective amount of a compound of formula (III), produced according to the method described above, or a pharmaceutically acceptable salt thereof.

The invention also provides a method of prophylactic or therapeutic treatment of hyperglycemia or diabetes, particularly type II diabetes, comprising a step of administering an

20   effective amount of a compound of formula (III), produced according to the method described above, or a pharmaceutically acceptable salt thereof. In this aspect of the invention the compound of formula (III) may be administered in combination with one or more other anti-hyperglycemic agents or anti-diabetic agents.

The invention also provides a method of prevention of diabetes, particularly type II

25   diabetes, in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound of formula (III), produced according to the method described above, or a pharmaceutically acceptable salt thereof.

All publications, including, but not limited to, patents and patent application cited in

30   this specification, are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as fully set forth.

The invention will now be described by reference to the following examples which are for illustrative purposes and are not to be construed as a limitation of the scope of the

35   present invention.

EXAMPLES

Materials and methods:

Column chromatography was carried out on SiO_2 (40–63 mesh). LCMS data were obtained using a Waters Symmetry 3.5μ C_{18} column (2.1 × 30.0mm, flow rate 0.8mL/min) eluting with solvent A (5% MeCN in H_2O) and solvent B (MeCN solution containing 0.1% HCO_2H) over 6min and UV detection at 220nm. Gradient information: 0.0–1.2min: 100% A; 1.2–3.8min: Ramp up to 10% A–90% B; 3.8–4.4min: Hold at 10% A–90% B; 4.4–5.5min: Ramp up to 100% B; 5.5–6.0min: Return to 100% A. The mass spectra were obtained employing an electrospray ionisation source in the positive (ES^+) ion mode. Prep HPLC purification was carried out using a Lunar 10 µ ODS2 (250 x 21.2mm; flow rate 20mL/min) eluting with solvent A (0.05% TFA, 10% MeCN, 90% water) and solvent B (0.05% TFA, 90% MeCN, 10% water) and UV detection at 215 nm. Gradient information: 0.0–0.2 min: 90% A, 10% B; 0.2–10.0 min: Ramp up to 10% A, 90% B; 10.0–15.0 min: 10% A, 90% B; 15.0–16.0 min: Return to 90% A, 10% B.

Preparation 1: 5-Fluorothiazol-2-ylamine hydrochloride (Method I)

NEt$_3$ (63.4mL, 455mmol) was added to a stirred suspension of 5-bromothiazol-2-ylamine hydrobromide (102.7g, 379mmol) in CH_2Cl_2 (1.5L). After 1h, TFAA (64.2mL, 455mmol) was added dropwise at 0°C over 15min. The mixture was allowed to warm to 20°C over 1h, before being stirred for an additional 2h. H_2O (600mL) was added and the resulting precipitate was collected. The aqueous layer of the filtrate was separated and extracted with $CHCl_3$ (3 × 300mL). The combined organic extracts were washed with brine, dried (Na_2SO_4), filtered and concentrated. The collected precipitate and residual solid were combined and triturated with EtOAc–n-C_6H_{14} to give N-(5-bromothiazol-2-yl)-2,2,2-trifluoroacetamide: δ_H (CDCl$_3$): 7.45 (1H, s), 13.05 (1H, br). n-BuLi (253mL of a 1.58M solution in hexanes, 403mmol) was added dropwise over 50min to a stirred solution of the above amide (50.0g, 183mmol) in anhydrous THF (1.3L) at –78°C. After 1.5h, a solution of N-fluorobenzenesulphonimide (86.0g, 275mmol) in anhydrous THF (250mL) was added dropwise over 30min. The mixture was stirred for 3h, before being warmed up to –30°C. H_2O (300mL) was added and the mixture was filtered through a Celite pad. The solid collected and Celite were washed with Et_2O (400mL) and H_2O (400mL). The organic layer of the filtrate was separated and extracted with water (2 × 400mL). The combined aqueous layers were washed with Et_2O (400mL), before being acidified to pH 6.5 with 2M HCl and

8

extracted with EtOAc (2 × 400mL). The combined organic extracts were washed with H$_2$O (2 × 400mL) and brine, before being dried (MgSO$_4$), filtered and concentrated. Column chromatography (EtOAc–n-C$_6$H$_{14}$, 1:3 to 1:2) gave N-(5-fluorothiazol-2-yl)-2,2,2-trifluoroacetamide: δ_H (CDCl$_3$): 7.13 (1H, d). AcCl (12.6mL, 175mmol) was added dropwise
5 to a stirred solution of this amide (15.7g, 73mmol) in MeOH (300mL) at 0°C. The mixture was stirred at 20°C for 30min, heated under reflux for 1h, and finally concentrated *in vacuo*. The residual solid was triturated with THF to give the title compound: δ_H (D$_2$O): 7.00 (1H, d).

Preparation 2: 5-Fluorothiazol-2-ylamine hydrochloride (Method II)

10 **a)   2-(Tert-butoxycarbonylamino)-5-fluorothiazole**

2-(Tert-butoxycarbonylamino)thiazole (10g, 0.050mol) in THF (0.2L) was cooled to -50°C under argon. tBuLi solution in pentane (60mL of a 1.7M solution, 0.102mol, 2.05eq) was added over a period of 30min and the temperature kept below -40°C. The suspension thus obtained was stirred at -50°C for 30min. A solution of N-fluorobenzenesulfonimide (NFSi)
15 was prepared (22.0g, 0.07mol in 70mL THF, 1.4eq) and 50mL of this solution (1eq) was added over a 5min period and the temperature kept under -40°C. The reaction was stirred for 20min at -50°C. Then tBuLi (10mL, 0.017mol, 0.35eq) and the NFSi solution (10mL, 0.4eq) added. The solution thus obtained was stirred at -50°C for 45min and then added to saturated NH$_4$Cl solution (300mL). The organic phase was separated and the aqueous phase further
20 washed with diethylether (100mL). The combined organic fractions were washed with brine (20mL) solution and dried (Na$_2$SO$_4$). The solvent was removed and the solid further dried to afford a brown solid. To this crude product was added trifluoroethanol (60mL) and formic acid (0.6mL). The suspension was heated to 85°C until it gave a solution. The flask was then cooled to RT and the precipitate thus formed filtered off to afford, after drying under high
25 vacuum, the title compound (6.4g, contains 2.3% of starting material according to HPLC at 275nm). After a second crystallisation (trifluoroethanol (22mL) and formic acid (0.22mL) for 20min at 85°C), the title compound was obtained as an off white solid (4.6g, contains 1% of starting material, 97.5% pure by HPLC). ^{1}H NMR (CDCl$_3$, 300 MHz) δ: 6.90 (1H, d, C_HCF), 1.60 (9H, s, Boc-H).

30 **b)   5-Fluorothiazol-2-ylamine hydrochloride**

2-(Tert-butoxycarbonylamino)-5-fluorothiazole (4.6g, 21.1mmol) was dissolved in dioxane (25mL). HCl gas was bubbled through the solution for 4h, then diethyl ether (50mL) was added to give a suspension which was filtered off. The solid was dried in high vacuum to afford the title compound (3.03g, 19.7mmol, 93% yield). ^{1}H NMR (D$_2$O) δ: 7.00 (1H, d); *m/z*
35 = 119.0 [M + H]$^+$.

Preparation 3: Ethyl (4-cyclopropylsulfanylphenyl)oxoacetate


AlCl$_3$ (104.6g, 0.79mol) was suspended in CH$_2$Cl$_2$ (1.15L) and cooled in an ice/salt

5   bath to 0°C with stirring. Ethyl chlorooxoacetate (84.8g, 0.62mol) was then added over a
period of 10min, during which time the temperature was maintained between 0 and 2°C. The
mixture was then stirred for a further 30min at 0°C, before the addition of
cyclopropylphenylsulfide (85.0g, 0.57mol) over a period of 45min, during which time the
temperature remained between 0 and 8°C. The resulting mixture was allowed to warm to

10   room temperature and stirred for a further 2h. After this time ice/water (275mL) was added,
with ice bath cooling maintaining the temperature at 20°C. The organic layer was separated
and washed with water (2 x 250mL), saturated NaHCO$_3$ solution (2 x 250mL) and again with
water (1 x 250mL). The organic fraction was then dried (MgSO$_4$) filtered and the solvent
removed to provide the title compound (134g, 94% yield). NMR was consistent with the

15   above structure.

**Preparation 4: Ethyl (4-cyclopropylsulfonylphenyl)oxoacetate**

20   To a stirred solution of Preparation 3 (49.4g, 0.2mol) in CH$_2$Cl$_2$ (180mL) was added a
solution of m-chloroperoxybenzoic acid (92.0g, 0.40mol, calc as 75% strength) in CH$_2$Cl$_2$
(650mL) over 45min with the temperature maintained at 15-25°C. TLC (CH$_2$Cl$_2$:ethyl acetate
1:10) showed that starting material still remained. Further m-chloroperoxybenzoic acid (3.4g)
in CH$_2$Cl$_2$ was added and the reaction stirred for 30min. A second TLC still showed the

25   presence of some starting material, and additional m-chloroperoxybenzoic acid (3.4g) was
added and the reaction stirred for a further 2h. TLC showed a small amount of starting
material so a final quantity of m-chloroperoxybenzoic acid (1.0g) was added and the reaction
continued for 1h. Sodium carbonate solution (2M, 500ml) was then added and the aqueous
layer was separated, the pH raised to 9-10 and reextracted with CH$_2$Cl$_2$. The organic extracts

30   were combined, washed with water (2 x 400ml), dried (MgSO$_4$), filtered and the solvent
removed under vacuum (54.1g, 96% yield). NMR was consistent with the above structure.

Preparation 5: (Tetrahydropyran-4-yl)methanol

5   To a suspension of LiAlH$_4$ (56g, 1.47mol) in diethyl ether (2L) under argon was
added methyl tetrahydro-2H-pyran-4-carboxylate (270g, 1.88mol) in diethyl ether (ca.
200mL) under reflux over a period of 1.75h. After addition was complete reflux was
continued for a further 1h. TLC (diethyl ether) indicated a small amount of ester remained, so
further LiAlH$_4$ (10g, 0.26mol) was added and reflux continued for 1h. Water (66mL) was
10   added, then 15% NaOH solution (66mL), followed by further water (198mL). The solid was
filtered and dried to give the crude product, which was redissolved in DCM (800 ml), dried
(MgSO$_4$),filtered and the solvent removed to afford the title compound (207 g, 94% yield).
NMR was consistent with the above structure.

15   **Preparation 6: Methanesulfonicacid (tetrahydropyran-4-yl)methyl ester**


       To a mixture of Preparation 5 (216.5g, 1.87mol) and triethylamine (299mL) in DCM
(1.3L) at <10°C was added under argon a solution of methanesulfonyl chloride (236g, 160mL)
20   in DCM (200mL) over 2h 50min, maintaining the temperature at 5-10°C throughout.
Subsequent washing with water (1L), 1M HCl (500mL), 5% NaHCO$_3$ (300mL), water
(300mL), drying (MgSO$_4$) and then removal of the solvent afforded the title compound (328g,
90% yield). NMR was consistent with the above structure.

25   **Preparation 7: 4-Iodomethyltetrahydropyran**

       A mixture of Preparation 6 (328g, 1.69mol) and sodium iodide (507g, 3.4mol) in
acetone (3.3L) was refluxed for 4h. TLC (diethyl ether) showed significant mesylate
30   remaining so further sodium iodide (127g, 0.65mol) was added and reflux continued for 16h.
The mixture was cooled and filtered. The resulting cake was washed with acetone, dried, and

then partitioned between diethyl ether (800mL) and water (800mL). The aqueous phase was re-extracted with diethyl ether (200mL), the ether extracts combined and washed with 10% sodium thiosulphate solution (300mL) which decolourised the extract. Final washing with water (300mL), drying (MgSO₄) and then removal of the solvent provided the title compound

5   (365g, 92% yield). NMR was consistent with the above structure.

Preparation 8: Triphenyl(tetrahydropyran4-ylmethyl)phosphonium iodide

10   A mixture of Preparation 7 (350g, 1.55M) and triphenylphosphine (406g, 1.55M) in acetonitrile (1.6L) was heated under reflux. After 27h the mixture was cooled and filtered, washed with diethyl ether and dried in air to provide a white solid (504g). Filtrate and washings were returned to reflux and concentrated to 750mL, reflux was maintained for 16h before cooling and dilution with diethyl ether (ca 1.2L). A precipitate formed which was

15   stirred for 30min before being filtered, washed with diethyl ether (2 x 300mL) and dried in air to yield a further crop (100g). Overall yield of the title compound (604 g, 80%). RT = 2.7min; *m/z* (ES⁺) = 361.2.

Preparation 9: (*E*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic

20   **acid**

To a suspension of Preparation 8 (2.49kg, 5.10mol) in dry THF (5L) maintained between -5 and 0°C was added a solution of lithium hexamethyldisilazide (1.05M, 4.39kg, 5.18mol) over 30min. The resulting mixture was then warmed to 15°C and stirred for 2h

25   before recooling to between 0 and 5°C. A solution of Preparation 4 (1.25kg, 4.43mol) in THF (2.5L) was then added over 1h, during which time the temperature was maintained between 0 and 5°C, before a period of 16h at between 20 and 25°C. Subsequently, brine (17% w/w, 3.8L) was added and the phases separated with the aid of additional brine (1.3L). The aqueous phase was reextracted with methyl t-butyl ether (2 x 2.5L) and the combined organic

30   extracts washed with brine (2 x 3.8L). The solvents were removed under vacuum at between

30 and 40°C. The residue was dissolved in methanol (15L) and aqueous sodium hydroxide (2M, 4.34L) added before heating at 65-67°C for 4h. The mixture was cooled and the solvents removed under vacuum at between 35 and 40°C until water started to distil. The residue was diluted with water (15L). The solid phosphine oxide was filtered off, washed

5   with water (2.5L) and the filtrate separated. The aqueous phase was washed with methyl t-butyl ether (5L and 3.5L), before acidification with hydrochloric acid solution (5M, 1.9L) in the presence of methyl t-butyl ether (10L). The organic phase was separated and the aqueous phase reextracted with methyl t-butyl ether (5L). The combined organic extracts were washed with saturated brine (2 x 1L) and the solvent removed under vacuum. Methanol (2L) was

10   added and then removed under vacuum, this step was then repeated. The residue was brought to a total weight of 4.0kg by addition of methanol and stirred at ambient temperature to crystallise the product. Filtration of the solid and washing with chilled (ca 0°C) methanol (500mL) gave, after vacuum drying at 40°C, the title compound (654g, 41% yield after correction for residual solvent). NMR was consistent with the above structure.

15

Example 1:   Preparation of (2R)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid

(E)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid (Preparation 9, 110g, 0.327mol) was dissolved in MeOH/Toluene 5:1 (1.4L). In a 40mL

20   Schlenk flask was placed [Rh(nbd)$_2$](BF$_4$) (30.5mg, 0.08mmol) and All-MOD-Mandyphos (90.4mg, 0.08mmol), dissolved in MeOH (10mL) and stirred for 1h at RT. This catalyst solution was then added to the (E)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid solution and transferred to a 2.5L autoclave. The autoclave was pressurized to 50 bar and heated to 30°C. After 18h the pressure was released and the solution transferred to

25   a 3L flask. Active charcoal (3g) was added to the reaction mixture, stirred for 1h and the charcoal removed by filtration. The solution was further filtered over Hyflo and a Zeta-Bond filter. The solution thus obtained was concentrated under partial pressure and the solid obtained further dried under high vacuum to give a solid (105g). The solid was placed in a 1.5L flask equipped with a mechanical stirrer, a thermometer and a dropping funnel.

30   Isobutylacetate (540mL) was added at RT and the suspension heated at 110°C until a clear solution was observed. Heptane (60mL) was added slowly at 110°C, the oil bath was then removed and the solution allowed to cool slowly. The reaction was stirred for a further 16h, the title compound filtered off and dried under high vacuum (77.2g, 70% yield, 99% ee). ^{1}H NMR (CDCl$_3$, 300.13 MHz) δ: 7.85 (2H, Aryl H, d, J$_{HH}$ = 6.6 Hz), 7.50 (2H, Aryl H, d, J$_{HH}$ =

6.6 Hz), 3.95 (br d, 2H), 3.80 (t, 1H, C*H*CH$_2$, J$_{HH}$ = 7.8 Hz), 3.35 (m, 2H), 2.45 (m, 1H), 2.10 (m, 1H), 1.75 (m, 1H), 1.60 (m, 2H), 1.50-1.20 (m, 5H), 1.05 (m, 2H).

Example 2:   Preparation of (2*R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-(5-
5   **fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide**

A mixture of CH$_2$Cl$_2$ (1.35L) and DMF (35.9mL, 0.465mol, 1.5eq) was cooled to -20°C and oxalylchloride (39.4mL) slowly added (0.465mol, 1.5eq). After stirring for 45min (2*R*)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid (Example 1, 105.0g, 0.310mol, 1eq) was added. The reaction was stirred at -20°C for 1h. Collidine
10   (185mL, 1.395mol, 4.5eq) was then slowly added. The reaction mixture was stirred for 15min and then 5-fluorothiazol-2-ylamine hydrochloride (Preparation 1, 52.7g, 0.341mol, 1.1eq) was added at -15°C. The resulting suspension was kept at -15°C for 2h after which the ice bath was removed and the reaction slowly warmed to RT over a period of 2h. The mixture was evaporated to dryness to afford a semi-solid to which was added portionwise 4N HCl solution
15   (1.5mL). The product was extracted with ethylacetate (3L) and the organic fraction further washed with water (1L) and saturated NaHCO$_3$ solution (1L). The solvent was removed under partial vacuum to give the title compound (135g). Characterising data was consistent with the formation of the title compound.

20   **Example 3:   Preparation of (2*R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-**
       (tetrahydropyran-4-yl)propionamide

In a 10L reaction vessel purged with N$_2$ were placed dichloromethane (2L) and N,N-dimethylformamide (54.7mL, 0.709mol). The solution was cooled to -10°C and oxalylchloride (60.0mL, 0.709mol) slowly added over 15min resulting into strong gas
25   evolution. The white suspension which formed was stirred until no more gas evolved then cooled to -20°C. A suspension of (2*R*)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid (Example 1, 200g, 0.590mol) in dichloromethane (1L) was added over 1h. The yellow solution was stirred for a further 0.5h, then cooled to -45°C and a solution of pyridine (51.0mL, 0.590mol) in dichloromethane (0.25L) added over 20min. While the
30   temperature was kept under -45°C, a suspension of 2-aminopyrazine (112.4g, 1.180mol) in THF (1.1L) and a solution of pyridine (154mL, 1.770mol) in dichloromethane (0.9L) were added in parallel over 1.25h. The cooling bath was removed and the orange suspension was stirred for a further 16h. The solution was concentrated under vacuum by means of a rotavap (250mbar, 50°C) and 3 x 800 mL portion of ethyl acetate were added and further distilled off.
35   To the brown oil were added ethyl acetate (2L) and aqueous HCl (2M, 2L). The phases were

14

separated and the organic phase further washed with aqueous HCl (2M, 2 x 1L). The aqueous phase were collected and washed with ethyl acetate (2L). The organic phases were collected and washed with water (2L) and a saturated solution of NaHCO$_3$ (2 x 1L). The HPLC analysis of the basic aqueous phase showed it contained some product and therefore was extracted

5   with ethyl acetate (2L). The organic fractions were collected and washed with water (1L) and brine (1L). The organic phase was dried over Na$_2$SO$_4$ and the suspension filtered off over a paper filter. The solvent was removed by means of a rotavap (125 mbar, 50°C) and ethanol was added portionwise (3 x 0.5L) to ensure complete removal of the ethyl acetate for the next step. A brown oil was isolated (248 g) which according to HPLC and ^{1}H NMR analyses was

10   96.5% pure and contained 16 % of ethanol (%ee > 98.0%). Corrected yield: 207.3g (84%). Characterising data was consistent with the formation of the title compound.

Example 4:   Preparation of (2*R*)-2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid

15   In a 300mL autoclave were placed (*E*)-2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid (5.4g, 15.5mmol, prepared by a process analogous to Preparation 9 and that described in PCT/US04/03968), and of MeOH/Toluene 5:1 solution (170mL). The autoclave was closed and evacuated by means of 10 cycles of vacuum / N$_2$ (10 bar). In a separate Schlenk flask are placed and degassed of MeOH/Toluene 5:1 solution

20   (10mL). Then the ligand (R)-(S)-MOD-Mandyphos (34.75mg, 0.033mmol) and [Rh(nbd)$_2$](BF$_4$) (11.6mg, 0.031mmol) were added to the Schlenk flask and the apparatus degassed by means of 5 cycles of vacuum / N$_2$. The thus prepared catalyst solution was transferred in the autoclave and 50 bar of H$_2$ pressure were applied. The reaction was stirred over night. The pressure was released. The solution was evaporated to dryness by means of a

25   rotavap to afford a beige solid (4.5g, 88%ee (R)).

             In a 250mL reaction vessel were added the crude product and isobutylacetate (80mL). The suspension was heated at 110°C until a clear solution was observed. Then heptane (8mL) was added at 110°C. The oil bath was then removed and the solution cooled down slowly. After standing over night, the precipitate was filtered off and the light beige crystalline solid

30   dried under vacuum (50°C, 200 mbar). After an IPC (HPLC: 93%ee) the crude product was dissolved again in isobutylacetate (80mL) at 110°C. Once the solution was clear, heptane (8mL) was added. The oil bath was then removed and the solution cooled down slowly. After standing over night, the precipitate was filtered off and the light beige crystalline solid dried under vacuum (50°C, 200 mbar). This afforded the title compound (3.8 g). Characterising

35   data was consistent with the formation of the title compound.

Example 5:   **Preparation of (2*R*)-2-(4-cyclobutanesulfonylphenyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)-3-(tetrahydropyran-4-yl)propionamide**

In a 100 mL three neck round bottom flask were placed CH$_2$Cl$_2$ (40mL) and (2*R*)-2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid (Example 4, 1.2g, 3.4 mmol). The solution was cooled to -20°C before DMF (0.273g, 3.74 mmol, 1.1eq.) and oxalylchloride (0.32g, 3.74 mmol, 1.1 eq) were added. The reaction was further stirred at -20°C for 1h to afford a slightly yellow solution. 1-Methyl-1*H*-3-aminopyrazole (0.99g, 10.2mmol, 3eq) was added at -20°C, then 0.55 g pyridine (0.55g, 6.8mmol, 2eq) was added over the course of 10min. After stirring at -20°C for 45min an IPC was taken. No more acid chloride was present. The reaction solution was warmed up to room temperature before taking up in ethylacetate (100mL) and washing twice with HCl (1M, 100mL) followed by washing twice with saturated NaHCO$_3$. The organic phase was dried over Na$_2$SO$_4$ before the solvent was removed. Crude product 1.2 g (82%); HPLC purity: >98%; Enantioselectivity: 98%. Characterising data was consistent with the formation of the title compound.

WHAT IS CLAIMED IS:

1.   A process for the production of a compound of formula (I):

(I)

wherein R is cyclopropyl or cyclobutyl, comprising the enantioselective hydrogenation of a compound of formula (II):


(II)

wherein the double bond is in the (E)-configuration and R is cyclopropyl or cyclobutyl.

2.   The process according to claim 1 which is conducted in the presence of a rhodium or ruthenium catalyst.

3.   The process according to claim 2 wherein the catalyst is generated in situ.

4.   The process according to claim 2 or 3 wherein the catalyst is generated from [Rh(nbd)$_2$]BF$_4$, [Rh(nbd)Cl]$_2$, or [RuI$_2$(p-cymeme)]$_2$ and a suitable ligand.

5.   The process according to claim 4 wherein the ligand is selected from atropisomeric diphosphines, which may have additionally a chiral carbon atom,
chiral diphosphines and other ferrocene ligands.

6.   The process according to claim 5 wherein the ligand is (R)-(S)-MOD-Mandyphos:

7.   The process according to claim 6 wherein the catalyst/ligand combination is [Rh(nbd)$_2$]BF$_4$ / (R)-(S)-MOD-Mandyphos.

8.   The process according to any one of the preceding claims wherein the hydrogenation pressure is in the range 15-100 bar.

9.   The process according to any one of the preceding claims wherein the hydrogenation is conducted at a temperature of from 30 to 80°C.

10.   The process according to any one of the preceding claims wherein the hydrogenation is conducted in solution.

11.   The process according to claim 10 wherein the solvent is an alcoholic solvent.

12.   The process according to claim 11 wherein the solvent comprises methanol, ethanol or iso-propanol.

13.   The process according to claim 12 wherein the solvent also comprises toluene.

14.   The process according to claim 13 wherein the solvent is a 1:1 to 10:1 v/v mixture of methanol and toluene or ethanol and toluene.

15.   The process according to any one of the preceding claims wherein the (R)-acid of formula (I) is further enantiomerically enriched by recrystallisation.

16.   The process according to claim 15 wherein the recrystallisation solvent is a mixture of isobutyl acetate and heptane at a ratio of 20:1 to 1:1v/v.

17.   A compound of formula (V):

(V)

wherein R is cyclopropyl or cyclobutyl.

5   18.   A process for the production of a compound of formula (III), or a pharmaceutically
acceptable salt thereof:

(III)

10   wherein R is cyclopropyl or cyclobutyl;

T together with the $-N=C-$ to which it is attached forms a heteroaryl ring, or a
heterocyclic ring where the $N=C$ bond is the only site of unsaturation;

R^3 and R^4 each independently are hydrogen, halogen, OCF_nH_{3-n}, methoxy, CO_2R^5,
cyano, nitro, CHO, $CONR^6R^7$, $CON(OCH_3)CH_3$, or C_{1-2}alkyl, heteroaryl, or C_{3-7}cycloalkyl

15   optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, $-NHCO_2CH_3$,
or $-N(C_{0-2}$alkyl$)(C_{0-2}$alkyl$)$ substituents; or R^3 and R^4 together form a 5–8-membered
aromatic, heteroaromatic, carbocyclic, or heterocyclic ring;

R^5 is hydrogen, or a C_{1-4}alkyl group, C_{2-4}alkenyl group, C_{2-4}alkynyl group, C_{3-7}cycloalkyl group, aryl group, heteroaryl group, or 4–7-membered heterocyclic group,

20   wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro,
hydroxy, C_{1-2}alkoxy, $-N(C_{0-2}$alkyl$)(C_{0-2}$alkyl$)$, C_{1-2}alkyl, C_{3-7}cycloalkyl, 4–7-membered
heterocyclic ring, CF_nH_{3-n}, aryl, heteroaryl, CO_2H, $-COC_{1-2}$alkyl, $-CON(C_{0-2}$alkyl$)(C_{0-2}$alkyl$)$, $SOCH_3$, SO_2CH_3, or $-SO_2N(C_{0-2}$alkyl$)(C_{0-2}$alkyl$)$ substituents;

R^6 and R^7 each independently are hydrogen, or C_{1-4}alkyl group, C_{3-7}cycloalkyl group,

25   aryl group, heteroaryl group, or 4–7-membered heterocyclic group, wherein any group
optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, C_{1-2}alkoxy, $-$
$N(C_{0-2}$alkyl$)(C_{0-2}$alkyl$)$, C_{1-2}alkyl, C_{3-7}cycloalkyl, 4–7-membered heterocyclic ring, CF_nH_{3-n},
aryl, heteroaryl, COC_{1-2}alkyl, $-CON(C_{0-2}$alkyl$)(C_{0-2}$alkyl$)$, $SOCH_3$, SO_2CH_3, or $-SO_2N(C_{0-2}$alkyl$)(C_{0-2}$alkyl$)$ substituents; or R^6 and R^7 together form a 6–8-membered heterobicyclic

19

ring system or a 4–8-membered heterocyclic ring which optionally is substituted with 1–2 independent C_{1-2}alkyl, CH_2OCH_3, COC_{0-2}alkyl, hydroxy, or SO_2CH_3 substituents; and

n is 1, 2 or 3;

comprising condensation of a compound of formula (I) produced according to any one of the preceding claims, or an activated derivative thereof, with an amine of formula (IV), or a salt thereof:

$$H_2N \underset{N}{\overset{R^3}{\underset{||}{\bigvee}}} \overset{R^4}{\underset{T}{\bigvee}}$$

(IV)

wherein T, R^3 and R^4 are as defined above.

19.   The process according to claim 18 wherein T together with the –N=C– to which it is attached forms a 3-pyrazolyl, 2-pyrazinyl or 2-thiazolyl ring, and R^3 and R^4 each independently are hydrogen, methyl or fluoro.

20.   The process according to claim 19 wherein T together with the –N=C– to which it is attached forms a 5-fluorothiazol-2-yl group.

21.   The process according to claim 19 wherein T together with the –N=C– to which it is attached forms a 1-methyl-1*H*-pyrazol-3-yl ring.

22.   The process according to claim 19 wherein T together with the –N=C– to which it is attached forms a 2-pyrazinyl ring.

23.   A pharmaceutical composition comprising a compound of formula (III), or a pharmaceutically acceptable salt thereof, produced according to the method of any one of claims 18 to 22, in combination with a pharmaceutically acceptable diluent or carrier.

24.   A method for the prophylactic or therapeutic treatment of a condition where activation of glucokinase is desirable comprising a step of administering an effective amount of a compound of formula (III), produced according to the method of any one of claims 18 to 22, or a pharmaceutically acceptable salt thereof.

25.   A method for the prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound of formula (III),

produced according to the method of any one of claims 18 to 22, or a pharmaceutically acceptable salt thereof.

26.   A method for the prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound of formula (III), produced according to the method of any one of claims 18 to 22, or a pharmaceutically acceptable salt thereof.

A. CLASSIFICATION OF SUBJECT MATTER

C07D405/06   C07D309/04   A61K31/4025

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/095438 A (F. HOFFMANN-LA ROCHE AG) 20 November 2003 (2003-11-20) pages 21-22, paragraph 34 claims 1,22	1-26
A	US 2001/003944 A1 (OKUBO RIKA ET AL) 21 June 2001 (2001-06-21) pages 5-6, paragraph 89 claim 1	1-26
A	WO 02/08209 A (F. HOFFMANN-LA ROCHE AG) 31 January 2002 (2002-01-31) claim 1	1-26

-/--

[X]	Further documents are listed in the continuation of box C.		[X]	Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 December 2005	19/12/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Samsam Bakhtiary, M

Form PCT/ISA/210 (second sheet) (January 2004)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2004/072031 A (OSI PHARMACEUTICALS, INC; FYFE, MATTHEW, COLIN, THOR; GARDNER, LISA, S) 26 August 2004 (2004-08-26) page 31, last paragraph – page 33, paragraph FIRST claims 1,31-34	1-26

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 03095438	A	20-11-2003	AU 2003232204 A1		11-11-2003
			BR 0309546 A		15-02-2005
			CA 2482346 A1		20-11-2003
			CN 1649859 A		03-08-2005
			EP 1501815 A1		02-02-2005
			HR 20040953 A2		30-06-2005
			MA 27113 A1		20-12-2004
US 2001003944	A1	21-06-2001	JP 2001242859 A		07-09-2001
WO 0208209	A	31-01-2002	AT 297907 T		15-07-2005
			AU 8760001 A		05-02-2002
			BR 0112658 A		24-06-2003
			CA 2416229 A1		31-01-2002
			CN 1443177 A		17-09-2003
			DE 60111534 D1		21-07-2005
			EP 1305301 A1		02-05-2003
			JP 2004504388 T		12-02-2004
			MX PA03000365 A		27-05-2003
			PT 1305301 T		30-09-2005
			ZA 200300173 A		07-04-2004
WO 2004072031	A	26-08-2004	AU 2004212500 A1		26-08-2004
			CA 2515670 A1		26-08-2004